Accentia Biopharmaceuticals (ABPI), Biovest International, Inc. Shrink Losses, Default on Debt
12/27/2012 8:16:32 AM
More...
|
Accentia Biopharmaceuticals (ABPI) Conducts Investigator Meeting in Preparation for New Multiple Sclerosis Drug Study for Cyrevia™
5/4/2012 10:05:40 AM
More...
|
Biovest International, Inc. to Seek Marketing Approval for BiovaxID® Personalized Lymphoma Cancer Vaccine in Canada
4/10/2012 10:04:42 AM
More...
|
Accentia Biopharmaceuticals (ABPI) Completes Sale of Analytica Group Subsidiary
12/20/2011 6:54:46 AM
More...
|
Accentia Biopharmaceuticals (ABPI) Has $10 Million Deal to Sell Analytica
11/7/2011 7:23:43 AM
More...
|
Accentia Biopharmaceuticals (ABPI) Announces that FDA Grants Orphan Drug Status for Revimmune(TM) Therapy for the Prevention of Graft-Versus-Host Disease in Bone Marrow Transplant
9/14/2011 9:20:40 AM
More...
|
Accentia Biopharmaceuticals (ABPI) and Biovest International, Inc. to Present at Biotechnology Industry Organization (BIO) International Convention
6/24/2011 9:14:21 AM
More...
|
Accentia Biopharmaceuticals (ABPI) Announces that FDA Grants Orphan Drug Status for Revimmune(TM) Therapy for the Treatment of Two Autoimmune Diseases: Systemic Sclerosis & Hemolytic Anemia
6/23/2011 8:39:33 AM
More...
|
Accentia Biopharmaceuticals (ABPI) Announces that Revimmune(TM) Autoimmune Disease Therapy is Featured in Peer-review Journal
5/4/2011 11:28:05 AM
More...
|
Accentia Biopharmaceuticals (ABPI) Announces Strategic Agreement with Baxter Healthcare Corporation (BAX)
11/29/2010 9:59:25 AM
More...
|
|